CytomX Therapeutics Inc., a San Francisco-based developer of proteolytically-activated antibodies, has expanded its Series B round by $11 million. The total round now stands at $41 million. Canaan Partners led the expansion, and was joined by return backers Third Rock Ventures and the Roche Venture Fund. www.cytomx.com R
EAD MORE AS YOU ENTER THE WORLDS OF @VENTURECAPITAL #DEALS @DANPRIMACK @CNNMONEY @FORTUNEMAGAZINE Tags: benny quetell,@resilient_ent,resilient media entertainment,venture capital
#PRIVATEEQUITY #VENTURECAPITAL, #HEDGEFUNDS, #INVESTMENTBANKING & a few fun things as well. Check US OUT: http://on.fb.me/vch6FQ http://linkd.in/oiB29lhttp://on.fb.me/sdaWqc http://bit.ly/uhH9hQ http://bit.ly/trKLuj http://goo.gl/Q376nkeywords: #PrivateEquity, #HedgeFunds, #VentureCapital, #InvestmentBanking, #AlernativeAssets, #CapitalMarkets, #MergersAndAcquisitions, #WallStreet, #IPO #ResilientMediaEntertainment, #IPO, @Resilient_Ent, #Film, #Music, #VideoGaming, #Media, #Fashion, #TV, #Technology #JointVentures #FaceBook #Magazines #PublicRelations #Radio #WealthManagementtags: +PrivateEquity, +HedgeFunds, +VentureCapital, +InvestmentBanking, +AlernativeAssets, +CapitalMarkets, +MergersAndAcquisitions, +WallStreet, +IPO +ResilientMediaEntertainment, +IPO, +@Resilient_Ent, +Film, +Music, +VideoGaming, +Media, +Fashion, +TV, +Technology +JointVentures +FaceBook, +Magazines +PublicRelations,+Radio, +WealthManagement
No comments:
Post a Comment
WHAT SAY YOU?